MannKind is growing revenue about 24% YoY and trades 80.9% below the $7.06 analyst target, but it is cash-burning with a -230.6% operating margin, three recent EPS misses and sole-supplier concentration risk.
Thesis pillars
- Strong Revenue Growth→Stable
- Deep Discount To Analyst Target↑Improving
- Cash Burn And Weak Quality→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 8, 2026, based on the 10-K filed Feb 26, 2026
MannKind Corporation (MNKD) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.85: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on behalf of partner United Therapeutics, alongside the V-Go insulin patch and Furoscix infusor, following its October 2025 acquisition of scPharma. The company... Read more
Sell if holding. Engine safety override at $3.85: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 6.2/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 95d clear, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated Nov 19, 2026Recent Developments — MannKind Corporation
Latest news
- NEWS MannKind Corporation Provides Business and Financial Update at Jefferies Global Healthcare Conference — fiscal.ai Nov 19, 2026 neutral
- NEWS MannKind Corporation Provides Business and Financial Update at UBS Global Biopharma Conference — fiscal.ai Nov 18, 2026 neutral
- NEWS MannKind Corporation to Participate in Upcoming Investor Conferences — fiscal.ai Nov 10, 2026 neutral
- NEWS RBC Capital Markets Raises Price Target on MannKind Corporation — fiscal.ai Nov 7, 2026 positive
- NEWS RBC Capital Maintains Sector Perform on MannKind, Raises Price Target to $5 — benzinga Nov 6, 2026 positive
Latest item Nov 19, 2026 · Generated 2026-11-22T11:37:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierAmphastar (sole insulin supplier for Afrezza)10-K Item 1: 'Currently, the only source of insulin that we have qualified for Afrezza is manufactured by Amphastar France Pharmaceuticals S.A.S. (“Amphastar”).'
- MEDIUMcounterpartyUnited Therapeutics (Tyvaso DPI commercialization)10-K Item 1A: 'A significant portion of our revenue is derived from royalties and collaboration and services revenue associated with United Therapeutics’ commercialization of Tyvaso DPI.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.85: Quality below floor (3.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.2/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $3.58. Score 6.2/10, moderate confidence.
Analyst target: $7.25 (+88.3% upside). Prior stop was $3.58. Stop-loss: $3.58.
Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza); Quality below floor (3.8 < 4.0); Value-trap signals (3/5): Margin compression (op margin -900.1%), Material insider selling (3 sells, 0.20% of cap), Negative free cash flow.
MannKind Corporation trades at a P/E of N/A (forward 24.4). TrendMatrix value score: 8.2/10. Verdict: Sell.
15 analysts rate MNKD, with a consensus score of 4.1/5. 9 analysts publish price targets averaging $8.
What does MannKind Corporation do?MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on...
MannKind Corporation markets Afrezza inhaled insulin and manufactures Tyvaso DPI for pulmonary arterial hypertension on behalf of partner United Therapeutics, alongside the V-Go insulin patch and Furoscix infusor, following its October 2025 acquisition of scPharma. The company depends on a single qualified insulin supplier, Amphastar, under a €120.1 million purchase commitment, and on United Therapeutics' continued commercial prioritization of Tyvaso DPI.